[Expression of IL-4 and IL-10 by PBMC and tumor tissues in cancer patients]

Using biological activity assay, the production of IL-4 and IL-10 by peripheral blood mononuclear cells (PBMC) was studied in patients with nasopharyngeal carcinoma and lymphoma. The IL-2, IL-4 and IFN gamma levels in both cancer patients were lower than that in normal subjects. In contrast, the IL-10 level was higher in both cancer patients. When rIL-2 was added into the cytokine production system, IL-2, IL-4, and IFN gamma level were upregulated in lymphoma patients. However, in the patients of nasopharyneal carcinoma, only IL-2 level was upregulated. IL-10 activity could not be affected by exogenous IL-2 in both cancer patients. The results of negative IL-4 activity and higher positive percentage (84.6%) of IL-10 activity in ascites from patients with ovarian carcinoma were corresponded to the patients with nasopharyngeal carcinoma and lymphoma. By using in situ hybridization technique, the expression of IL-4 and IL-10 was studied in tumor tissues from patients with gastric, esophageal and breast carcinomas. There was no differences of the percentage of IL-4 and IL-10 expression among three kinds of tumor tissues, the range of positive percentage was 40%-70%. These results indicate that the correction of abnormal upregulation of IL-10 activity should be considered for cancer immunotherapy.